{"protocolSection": {"identificationModule": {"nctId": "NCT00574119", "orgStudyIdInfo": {"id": "IRB 070824"}, "organization": {"fullName": "Vanderbilt University Medical Center", "class": "OTHER"}, "briefTitle": "Effect of Aldosterone on Energy Starvation in Heart Failure", "officialTitle": "Effect of Aldosterone on Energy Starvation in Heart Failure"}, "statusModule": {"statusVerifiedDate": "2019-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-12"}, "primaryCompletionDateStruct": {"date": "2012-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-12-13", "studyFirstSubmitQcDate": "2007-12-14", "studyFirstPostDateStruct": {"date": "2007-12-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-05-08", "resultsFirstSubmitQcDate": "2019-05-30", "resultsFirstPostDateStruct": {"date": "2019-06-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-05-30", "lastUpdatePostDateStruct": {"date": "2019-06-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Marvin W. Kronenberg, M.D.", "investigatorTitle": "Professor of Medicine and Radiology", "investigatorAffiliation": "Vanderbilt University"}, "leadSponsor": {"name": "Vanderbilt University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "We plan to study the concept of \"energy starvation\" in heart failure by evaluation of patients with nonischemic dilated cardiomyopathy (NIDCM) (heart failure with reduced heart pump function due to causes other than heart attack). We will use a combination of positron emission tomography and magnetic resonance imaging to study metabolism, anatomy, function, blood flow and efficiency, before and after 6 months' treatment with the drug spironolactone which blocks the deleterious effects of the hormone aldosterone on the myocardium (heart muscle).", "detailedDescription": "Preliminary results showed reduced subendocardial myocardial perfusion reserve in NIDCM compared to normal subjects, and that the degree of impaired perfusion reserve was related to the oxidative metabolic rate as measured by positron emission tomography."}, "conditionsModule": {"conditions": ["Heart Failure", "Nonischemic Dilated Cardiomyopathy"], "keywords": ["heart failure", "positron emission tomography", "magnetic resonance imaging", "myocardial energetics", "myocardial perfusion"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 16, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Results with spironolactone", "type": "EXPERIMENTAL", "description": "patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.", "interventionNames": ["Drug: spironolactone"]}], "interventions": [{"type": "DRUG", "name": "spironolactone", "description": "spironolactone 50 mg daily for 6 months", "armGroupLabels": ["Results with spironolactone"], "otherNames": ["Aldactone"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Left Ventricular Work-metabolic Index (WMI) at Baseline", "description": "WMI=\\[left ventricular stroke work/decay rate of 11C-acetate\\]", "timeFrame": "baseline"}, {"measure": "Left Ventricular Work-metabolic Index (WMI) at 6 Months", "description": "WMI=\\[left ventricular stroke work/decay rate of 11C-acetate\\]", "timeFrame": "6 months"}, {"measure": "Myocardial Perfusion Reserve Index (MPRI) by Magnetic Resonance Imaging at Baseline", "description": "MPRI =calculated myocardial perfusion reserve index based on Gadolinium accretion into myocardium. MPRI was calculated as the ratio of stress/rest relative perfusion upslope, corrected for LV cavity upslope.", "timeFrame": "baseline"}, {"measure": "Myocardial Perfusion Index Reserve (MPRI) by Magnetic Resonance Imaging at 6 Months", "description": "MPRI =calculated myocardial perfusion reserve index based on Gadolinium accretion into myocardium. MPRI was calculated as the ratio of stress/rest relative perfusion upslope, corrected for LV cavity upslope.", "timeFrame": "6 months"}, {"measure": "Change in Myocardial Fibrosis (T1 Time) by Magnetic Resonance Imaging", "description": "T1=left ventricular relaxation rate on magnetic resonance imaging, which is correlated with interstitial fibrosis.", "timeFrame": "baseline and 6 months"}], "secondaryOutcomes": [{"measure": "6 Minute Walk Test (6MWT) at Baseline", "description": "6MWT assesses distance walked over 6 minutes", "timeFrame": "baseline"}, {"measure": "6 Minute Walk Test (6MWT) at 6 Months", "description": "6MWT assesses distance walked over 6 minutes", "timeFrame": "6 months"}, {"measure": "Minnesota Living With Heart Failure Questionnaire,at Baseline", "description": "The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. Each question is scored from 0 (none or not applicable) to 5 (very much). Total scores range from 0-105. Low scores indicate less adverse impact, while higher scores reflect more adverse impact of heart failure.", "timeFrame": "baseline"}, {"measure": "Minnesota Living With Heart Failure Questionnaire.at 6 Months", "description": "The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. Each question is scored from 0 (none or not applicable) to 5 (very much). Total scores range from 0-105. Low scores indicate less adverse impact, while higher scores reflect more adverse impact of heart failure.", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years or older\n* Nonischemic dilated cardiomyopathy\n* Left ventricular ejection fraction 35% or less\n* Stable heart failure symptoms\n* Able to undergo both positron emission tomography and magnetic resonance imaging with gadolinium\n* Able to tolerate treatment with spironolactone\n\nExclusion Criteria:\n\n* Serum potassium \\>5.0\n* Serum creatinine \\>2.5\n* Contraindications to magnetic resonance imaging such as internal cardioverter-defibrillator.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Marvin W Kronenberg, MD", "affiliation": "Vanderbilt University School of Medicine", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Vanderbilt Heart and Vascular Institute", "city": "Nashville", "state": "Tennessee", "zip": "37232", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}]}, "referencesModule": {"references": [{"pmid": "33403831", "type": "DERIVED", "citation": "Lawson MA, Hansen DE, Gupta DK, Bell SP, Adkisson DW, Mallugari RR, Sawyer DB, Ooi H, Kronenberg MW. Modification of ventriculo-arterial coupling by spironolactone in nonischemic dilated cardiomyopathy. ESC Heart Fail. 2021 Apr;8(2):1156-1166. doi: 10.1002/ehf2.13161. Epub 2021 Jan 5."}, {"pmid": "30286821", "type": "DERIVED", "citation": "Bradham WS, Bell SP, Huang S, Harrell FE Jr, Adkisson DW, Lawson MA, Sawyer DB, Ooi H, Kronenberg MW. Timing of Left Ventricular Remodeling in Nonischemic Dilated Cardiomyopathy. Am J Med Sci. 2018 Sep;356(3):262-267. doi: 10.1016/j.amjms.2018.06.003. Epub 2018 Jun 8."}, {"pmid": "25515841", "type": "DERIVED", "citation": "Lawson MA, Bell SP, Adkisson DW, Wang L, Ooi H, Sawyer DB, Kronenberg MW. High reproducibility of adenosine stress cardiac MR myocardial perfusion imaging in patients with non-ischaemic dilated cardiomyopathy. BMJ Open. 2014 Dec 16;4(12):e005984. doi: 10.1136/bmjopen-2014-005984."}, {"pmid": "25164945", "type": "DERIVED", "citation": "Bell SP, Adkisson DW, Lawson MA, Wang L, Ooi H, Sawyer DB, Kronenberg MW. Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy. J Am Heart Assoc. 2014 Aug 27;3(4):e000883. doi: 10.1161/JAHA.114.000883."}, {"pmid": "24331202", "type": "DERIVED", "citation": "Bell SP, Adkisson DW, Ooi H, Sawyer DB, Lawson MA, Kronenberg MW. Impairment of subendocardial perfusion reserve and oxidative metabolism in nonischemic dilated cardiomyopathy. J Card Fail. 2013 Dec;19(12):802-10. doi: 10.1016/j.cardfail.2013.10.010. Epub 2013 Oct 29."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Results With Spironolactone", "description": "patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.\n\nspironolactone: spironolactone 50 mg daily for 6 months"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "one patient excluded prior to drug administration due to normal LV function.", "groups": [{"id": "BG000", "title": "Results With Spironolactone", "description": "patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.\n\nspironolactone: spironolactone 50 mg daily for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "15"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "52", "lowerLimit": "45", "upperLimit": "54"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "15"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "10"}]}]}]}, {"title": "Race and Ethnicity Not Collected", "populationDescription": "Race and Ethnicity were not collected from any participant.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Left Ventricular Work-metabolic Index (WMI) at Baseline", "description": "WMI=\\[left ventricular stroke work/decay rate of 11C-acetate\\]", "populationDescription": "12 patients completed study", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "(x10^6), mL x mm Hg/m^2", "timeFrame": "baseline", "groups": [{"id": "OG000", "title": "Results With Spironolactone", "description": "patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.\n\nspironolactone: spironolactone 50 mg daily for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.4", "lowerLimit": "2.2", "upperLimit": "3.9"}]}]}]}, {"type": "PRIMARY", "title": "Left Ventricular Work-metabolic Index (WMI) at 6 Months", "description": "WMI=\\[left ventricular stroke work/decay rate of 11C-acetate\\]", "populationDescription": "12 patients completed study", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "(x10^6), mL x mm Hg/m^2", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Results With Spironolactone", "description": "patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.\n\nspironolactone: spironolactone 50 mg daily for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.4", "lowerLimit": "4.4", "upperLimit": "5.9"}]}]}]}, {"type": "PRIMARY", "title": "Myocardial Perfusion Reserve Index (MPRI) by Magnetic Resonance Imaging at Baseline", "description": "MPRI =calculated myocardial perfusion reserve index based on Gadolinium accretion into myocardium. MPRI was calculated as the ratio of stress/rest relative perfusion upslope, corrected for LV cavity upslope.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "MPRI", "timeFrame": "baseline", "groups": [{"id": "OG000", "title": "Results With Spironolactone", "description": "patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.\n\nspironolactone: spironolactone 50 mg daily for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.72", "lowerLimit": "1.67", "upperLimit": "1.87"}]}]}]}, {"type": "PRIMARY", "title": "Myocardial Perfusion Index Reserve (MPRI) by Magnetic Resonance Imaging at 6 Months", "description": "MPRI =calculated myocardial perfusion reserve index based on Gadolinium accretion into myocardium. MPRI was calculated as the ratio of stress/rest relative perfusion upslope, corrected for LV cavity upslope.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "MPRI", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Results With Spironolactone", "description": "patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.\n\nspironolactone: spironolactone 50 mg daily for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.80", "lowerLimit": "1.76", "upperLimit": "1.92"}]}]}]}, {"type": "PRIMARY", "title": "Change in Myocardial Fibrosis (T1 Time) by Magnetic Resonance Imaging", "description": "T1=left ventricular relaxation rate on magnetic resonance imaging, which is correlated with interstitial fibrosis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "msec", "timeFrame": "baseline and 6 months", "groups": [{"id": "OG000", "title": "Results With Spironolactone", "description": "patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.\n\nspironolactone: spironolactone 50 mg daily for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6", "spread": "37"}]}]}]}, {"type": "SECONDARY", "title": "6 Minute Walk Test (6MWT) at Baseline", "description": "6MWT assesses distance walked over 6 minutes", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "meters", "timeFrame": "baseline", "groups": [{"id": "OG000", "title": "Results With Spironolactone", "description": "patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.\n\nspironolactone: spironolactone 50 mg daily for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "521", "lowerLimit": "468", "upperLimit": "530"}]}]}]}, {"type": "SECONDARY", "title": "6 Minute Walk Test (6MWT) at 6 Months", "description": "6MWT assesses distance walked over 6 minutes", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "meters", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Results With Spironolactone", "description": "patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.\n\nspironolactone: spironolactone 50 mg daily for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "542", "lowerLimit": "523", "upperLimit": "604"}]}]}]}, {"type": "SECONDARY", "title": "Minnesota Living With Heart Failure Questionnaire,at Baseline", "description": "The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. Each question is scored from 0 (none or not applicable) to 5 (very much). Total scores range from 0-105. Low scores indicate less adverse impact, while higher scores reflect more adverse impact of heart failure.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "score on a scale", "timeFrame": "baseline", "groups": [{"id": "OG000", "title": "Results With Spironolactone", "description": "patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.\n\nspironolactone: spironolactone 50 mg daily for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "54", "lowerLimit": "26", "upperLimit": "71"}]}]}]}, {"type": "SECONDARY", "title": "Minnesota Living With Heart Failure Questionnaire.at 6 Months", "description": "The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. Each question is scored from 0 (none or not applicable) to 5 (very much). Total scores range from 0-105. Low scores indicate less adverse impact, while higher scores reflect more adverse impact of heart failure.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "score on a scale", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Results With Spironolactone", "description": "patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.\n\nspironolactone: spironolactone 50 mg daily for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22", "lowerLimit": "20", "upperLimit": "44"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "6 months", "eventGroups": [{"id": "EG000", "title": "Results With Spironolactone", "description": "patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.\n\nspironolactone: spironolactone 50 mg daily for 6 months", "deathsNumAffected": 0, "deathsNumAtRisk": 16, "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 2, "otherNumAtRisk": 16}], "otherEvents": [{"term": "shortness of breath", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "shortness of breath during test", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}]}, {"term": "pacemaker insertion", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "pacemaker insertion by personal physician", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Marvin W. Kronenberg,M.D.", "organization": "Vanderbilt University School of Medicine", "email": "marvin.w.kronenberg@vumc.org", "phone": "615 936-7437"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2011-02-22", "uploadDate": "2019-05-30T10:32", "filename": "Prot_SAP_000.pdf", "size": 452967}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000009202", "term": "Cardiomyopathies"}, {"id": "D000002311", "term": "Cardiomyopathy, Dilated"}, {"id": "D000013217", "term": "Starvation"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006332", "term": "Cardiomegaly"}, {"id": "D000083083", "term": "Laminopathies"}, {"id": "D000030342", "term": "Genetic Diseases, Inborn"}, {"id": "D000044342", "term": "Malnutrition"}, {"id": "D000009748", "term": "Nutrition Disorders"}], "browseLeaves": [{"id": "M12154", "name": "Cardiomyopathies", "asFound": "Cardiomyopathy", "relevance": "HIGH"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M5567", "name": "Cardiomyopathy, Dilated", "asFound": "Dilated Cardiomyopathy", "relevance": "HIGH"}, {"id": "M16010", "name": "Starvation", "asFound": "Starvation", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M9420", "name": "Cardiomegaly", "relevance": "LOW"}, {"id": "M2392", "name": "Laminopathies", "relevance": "LOW"}, {"id": "M23686", "name": "Genetic Diseases, Inborn", "relevance": "LOW"}, {"id": "M25306", "name": "Malnutrition", "relevance": "LOW"}, {"id": "M12684", "name": "Nutrition Disorders", "relevance": "LOW"}, {"id": "T1876", "name": "Dilated Cardiomyopathy", "asFound": "Dilated Cardiomyopathy", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC16", "name": "Diseases and Abnormalities at or Before Birth"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000013148", "term": "Spironolactone"}], "ancestors": [{"id": "D000000451", "term": "Mineralocorticoid Receptor Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000062865", "term": "Diuretics, Potassium Sparing"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}], "browseLeaves": [{"id": "M15943", "name": "Spironolactone", "asFound": "Tape", "relevance": "HIGH"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M3797", "name": "Mineralocorticoid Receptor Antagonists", "relevance": "LOW"}, {"id": "M11871", "name": "Mineralocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}]}}, "hasResults": true}